Business
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediat
About this update from Travere Therapeutics, Inc.
[{"type":"image","alt":"Ligand Pharmaceuticals","displaySize":"","headline":null,"caption":"Ligand Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/e824ed3c4822e04f01467c6db4017595"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RxGj7s7LJi3M86PIFXFxrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/e824ed3c4822e04f01467c6db4017595","width":300,"height":105}},"lazy":false},{"type":"text","content":"FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure","length":114,"tagName":"p"},{"type":"text","content":"Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI","length":69,"tagName":"p"},{"type":"text","content":"JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.","length":425,"tagName":"p"},{"type":"text","content":"FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, marking its expansion beyond IgA nephropathy (IgAN) into a second rare kidney disease. FILSPARI is currently the most commonly prescribed FDA-approved medicine for IgAN and Ligand is entitled to a 9% royalty on worldwide net sales.","length":318,"tagName":"p"},{"type":"text","content":"“We congratulate Travere for achieving this incredible milestone, which builds on other recent successes for FILSPARI,” said Todd Davis, CEO of Ligand. “As the first and only FDA-approved medicine indicated for this rare and serious condition, FILSPARI offers new hope for kidney patients. This approval positions FILSPARI to be a key driver of long-term royalty growth for Ligand in 2026 and beyond.”","length":401,"tagName":"p"},{"type":"text","content":"People with FSGS who do not have nephrotic syndrome span across types of FSGS and represent a population aligned with the KDIGO guidelines for treating glomerular diseases. Nephrotic syndrome is commonly defined as the presenc...